{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:32:09Z","timestamp":1781839929533,"version":"3.54.5"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","cpcardiology.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.cpcardiol.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T09:30:18Z","timestamp":1486027818000},"page":"146-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention"],"prefix":"10.1016","volume":"42","author":[{"given":"Carl J.","family":"Lavie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Scheiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2017.01.006_bib1","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib2","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.109.934786","article-title":"Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design","volume":"123","author":"Hong","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib3","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","article-title":"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Furie","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib5","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib6","first-page":"e123","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"134","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"Br Med J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib9","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.2012.5034","article-title":"Association of aspirin use with major bleeding in patients with and without diabetes","volume":"307","author":"De Berardis","year":"2012","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garcia Rodriguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2010.10.027","article-title":"Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey","volume":"156","author":"Cayla","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/11589200-000000000-00000","article-title":"Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk","volume":"4","author":"Moberg","year":"2011","journal-title":"Patient"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","article-title":"Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin","volume":"22","author":"Yeomans","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10620-005-1281-1","article-title":"Endoscopy in asymptomatic minidose aspirin consumers","volume":"50","author":"Niv","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FJC.0000000000000387","article-title":"Aspirin use in secondary cardiovascular protection and the development of aspirin-associated erosions and ulcers","volume":"68","author":"Goldstein","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.amjmed.2009.09.031","article-title":"Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease","volume":"123","author":"Barkun","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib17","first-page":"1289","article-title":"Features associated with painless peptic ulcer bleeding","volume":"92","author":"Wilcox","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib18","doi-asserted-by":"crossref","first-page":"e0160046","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies","volume":"11","author":"Garcia Rodriguez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib20","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clinthera.2010.04.009","article-title":"Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events","volume":"32","author":"Scheiman","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.12240","article-title":"The aspirin cardiovascular\/gastrointestinal risk calculator\u2014a tool to aid clinicians in practice","volume":"37","author":"Lanas","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11585320-000000000-00000","article-title":"Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding?","volume":"71","author":"Sostres","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","article-title":"Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial","volume":"152","author":"Sung","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib25","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1152\/physrev.00004.2008","article-title":"Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn\u2019t the stomach digest itself?","volume":"88","author":"Wallace","year":"2008","journal-title":"Physiol Rev"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40264-016-0421-1","article-title":"Contemporary reflections on the safety of long-term aspirin treatment for the secondary prevention of cardiovascular disease","volume":"39","author":"Fanaroff","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib28","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.bbalip.2012.04.002","article-title":"Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine","volume":"1821","author":"Lichtenberger","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0016-5085(85)80185-2","article-title":"Effect of 16,16-dimethyl prostaglandin E2 on the surface hydrophobicity of aspirin-treated canine gastric mucosa","volume":"88","author":"Lichtenberger","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1741-7015-4-22","article-title":"Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications","volume":"4","author":"Hernandez-Diaz","year":"2006","journal-title":"BMC Med"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.52.2.186","article-title":"Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults","volume":"52","author":"Rosenstock","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12876-014-0205-y","article-title":"Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular events","volume":"14","author":"Ruigomez","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/11318440-000000000-00000","article-title":"Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation","volume":"10","author":"Herlitz","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib34","first-page":"1","article-title":"Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease","volume":"3","author":"Martin-Merino","year":"2012","journal-title":"Pragmat Obs Res"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11584410-000000000-00000","article-title":"The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk","volume":"10","author":"Pratt","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib36","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cgh.2012.08.034","article-title":"Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events","volume":"11","author":"Derogar","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib38","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/pds.3840","article-title":"Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality","volume":"24","author":"Hamood","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib39","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.jacc.2015.12.068","article-title":"Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy","volume":"67","author":"Vaduganathan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1155\/2013\/596015","article-title":"Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: a meta-analysis of randomized clinical trials and observational studies","volume":"27","author":"Valkhoff","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11886-016-0749-2","article-title":"The ADAPTABLE trial and aspirin dosing in secondary prevention for patients with coronary artery disease","volume":"18","author":"Johnston","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib44","first-page":"B4969","article-title":"National consensus on management of peptic ulcer bleeding in Denmark 2014","volume":"61","author":"Laursen","year":"2014","journal-title":"Dan Med J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib45","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/j.1572-0241.2008.01995.x","article-title":"Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin","volume":"103","author":"Yeomans","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib46","first-page":"245","article-title":"Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events","volume":"9","author":"Sylvester","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/hrt.2010.217547","article-title":"Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)","volume":"97","author":"Scheiman","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.gastro.2011.03.049","article-title":"Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy","volume":"141","author":"Lin","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2011.04707.x","article-title":"Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention","volume":"34","author":"Saini","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib50","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2011.05.020","article-title":"Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis","volume":"9","author":"Lanas","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib51","doi-asserted-by":"crossref","first-page":"56S","DOI":"10.1592\/phco.23.13.56S.31932","article-title":"History of acid suppression: focus on the hospital setting","volume":"23","author":"Garnett","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4292\/wjgpt.v5.i2.57","article-title":"Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing","volume":"5","author":"McRorie","year":"2014","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0016-5085(94)94341-9","article-title":"Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?","volume":"106","author":"Merki","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2016.09.006","article-title":"Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin","volume":"152","author":"Chan","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib56","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.3748\/wjg.v21.i17.5382","article-title":"Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries","volume":"21","author":"Mo","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib57","first-page":"481","article-title":"The clinical effect of esomeprazole in prevention of low dose aspirin induced gastric mucosal injury","volume":"29","author":"Guo","year":"2012","journal-title":"Chin J Dig"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib58","first-page":"100","article-title":"The effect of rabeprazole in prevention of low dose aspirin induced gastric injury","volume":"14","author":"Hu","year":"2012","journal-title":"MMJC"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2009.09.063","article-title":"Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions","volume":"138","author":"Ng","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ajg.2011.385","article-title":"Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction","volume":"107","author":"Ng","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib61","first-page":"79","article-title":"The effect of rabeprazole in prevention of low-dose aspirin induced gastric mucosal injury in 40 elder patients","volume":"6","author":"Sun","year":"2012","journal-title":"Chin J Mod Drug"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib62","first-page":"191","article-title":"The efficacy in prevention of upper gastrointestinal injury in patients of acute cornary syndrome with esomeprazole, famotidine and hydrotalcite","volume":"10","author":"Wang","year":"2012","journal-title":"Chin J Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib63","first-page":"114","article-title":"The clinical effect of lansoprazole in prevention of low dose aspirin induced gastric mucosal injury","volume":"24","author":"Wang","year":"2016","journal-title":"Strait Pharm J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/17512433.2014.945428","article-title":"Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin","volume":"7","author":"Gesheff","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib65","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.amjcard.2013.05.051","article-title":"Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United Kingdom primary care","volume":"112","author":"Martin Merino","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ahj.2014.05.017","article-title":"PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325mg and immediate-release omeprazole 40mg) versus enteric-coated aspirin 325mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies","volume":"168","author":"Whellan","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003044","article-title":"Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care","volume":"3","author":"de Jong","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib68","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.3748\/wjg.v18.i24.3167","article-title":"Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications","volume":"18","author":"Zhu","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1155\/2010\/397610","article-title":"The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy","volume":"24","author":"Superceanu","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib70","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/joim.12103","article-title":"Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding\u2014a cohort study of the effects of proton pump inhibitor use patterns","volume":"274","author":"Hedberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib71","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0194599816648298","article-title":"Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews","volume":"155","author":"Abramowitz","year":"2016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib72","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib74","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib75","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"Wurtz","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib76","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"Br Med J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib77","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2017.01.006_bib78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0889-8553(05)70247-8","article-title":"NSAIDs, gastrointestinal injury, and cytoprotection","volume":"25","author":"Scheiman","year":"1996","journal-title":"Gastroenterol Clin North Am"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280617300166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280617300166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T01:53:23Z","timestamp":1568771603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280617300166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0146280617300166"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2017.01.006","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}